-to-use’ GC pen, is not available. Prednisone (PN) suppositories have been recommended by recent guidelines ( 14 ). However, the guidelines indicate that the level of evidence is low, as the rectal administration of PN (REC-PN), which is approved for the
Stephanie Burger-Stritt, Linda Bachmann, Max Kurlbaum, and Stefanie Hahner
Yang Lv, Ning Pu, Wei-lin Mao, Wen-qi Chen, Huan-yu Wang, Xu Han, Yuan Ji, Lei Zhang, Da-yong Jin, Wen-Hui Lou, and Xue-feng Xu
Introduction Rectal neuroendocrine neoplasms (rectal NENs) are a series of heterogeneous neoplasms, which make up the third commonest neoplasms of rectum ( 1 , 2 ). The incidence and prevalence of rectal NENs has been increasing dramatically
Yuan Fang, Xuehong Zhang, Huilin Xu, Stephanie A Smith-Warner, Dongli Xu, Hong Fang, and Wang Hong Xu
), Rectal (C19–C20), Liver (C22), Pancreas (C25), Trachea/bronchus and lung (C33–C34), Prostate (C61), Breast (C50), Corpus uteri (C53) and Thyroid (C73). The record linkage was conducted in April 2017. This study was approved by the Institutional Review
Anna Malczewska, Kjell Oberg, and Beata Kos-Kudla
. Cohorts The study cohort comprised 258 NENs, including gastroenteropancreatic (GEP) NENs ( n = 215): pancreatic, PNENs, n = 67; small intestine (midgut), SINENs, n = 40; rectal, RNENs, n = 45; gastric, GNENs, n = 44; appendiceal, ANENs, n = 10
L Johnsen, N B Lyckegaard, P Khanal, B Quistorff, K Raun, and M O Nielsen
). Heart rates were assessed using a stethoscope and a stop-watch, counting the heart-beats for 60 s, and using the average value obtained from three repeated determinations. Rectal temperatures were measured using an electronic standard rectal thermometer
Josephina G. Kuiper, Aline C. Fenneman, Anne H. van der Spek, Elena Rampanelli, Max Nieuwdorp, Myrthe P.P. van Herk-Sukel, Valery E.p.p. Lemmens, Ernst J. Kuipers, Ron M.C. Herings, and Eric Fliers
Objective: Whether an association between oral levothyroxine use, leading to supraphysiological exposure of the colon to thyroid hormones, and risk of colorectal cancer exists in humans is unclear. We therefore aimed to assess whether the use of levothyroxine is associated with a reduced risk of colorectal cancer in a linked cohort of pharmacy and cancer data.
Design: Population-based matched case-control study.
Methods: A total of 28,121 patients diagnosed with colorectal cancer between 1998-2014 were matched to 106,086 controls. Multivariable logistic regression was used to estimate the association between levothyroxine use and occurrence of colorectal cancer, adjusted for potential confounders. Results were stratified by gender, age, tumour subtype and staging as well as treatment duration and dosing.
Results: A total of 1066 colorectal cancer patients (4%) and 4024 (4%) controls had used levothyroxine at any point before index date (adjusted odds ratio 0.95 [0.88-1.01]). Long-term use of levothyroxine was seen in 323 (30%) colorectal cancer patients and 1111 (28%) controls (adjusted odds ratio 1.00 [0.88-1.13]). Stratification by tumour subsite showed a borderline significant risk reduction of rectal cancer, while this was not seen for proximal colon cancer or distal colon cancer. There was no relationship with treatment duration or with levothyroxine dose.
Conclusions: In this study, no reduced risk of colorectal cancer was seen in levothyroxine users. When stratifying by tumour subsite, a borderline significant risk reduction of rectal cancer was found and may warrant further research.
Jakob Kirkegård, Dora Körmendiné Farkas, Jens Otto Lunde Jørgensen, and Deirdre P Cronin-Fenton
almost all cancer diagnoses in Denmark since 1943 ( 10 ). We considered the following cancers: esophageal, stomach, small intestinal, colon, rectal, anal, liver, gallbladder and biliary tract and pancreatic cancer. We excluded all patients diagnosed with
Jordyn Silverstein, Wesley Kidder, Susan Fisher, Thomas A Hope, Samantha Maisel, Dianna Ng, Jessica Van Ziffle, Chloe E Atreya, and Katherine Van Loon
diagnosis, she had lost 30 pounds from her pre-pregnancy weight, was incontinent of feces and had developed a rectovaginal fistula. Magnetic resonance imaging of the pelvis at diagnosis revealed a bulky infiltrative high rectal mass extending into the right
Yue-Yue Wang, Qian Wu, Lu Chen, Wen Chen, Tao Yang, Xiao-Quan Xu, Fei-Yun Wu, Hao Hu, and Huan-Huan Chen
tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance . Investigative Radiology 2015 50 239 – 245 . ( https://doi.org/10.1097/RLI.0000000000000116 ) 11 Su GY Xu XQ Zhou Y Zhang H Si
M S Elston, V B Crawford, M Swarbrick, M S Dray, M Head, and J V Conaglen
prostatism, and a hard irregular prostate gland was present on digital rectal examination. The patient’s prostate-specific antigen (PSA) was normal ( Table 1 ). Figure 1 (A) CT imaging showing irregular prostate margins with possible extracapular